Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit

por Sun, Haowei (Linda), Chan, Stella, Yenson, Paul, Jackson, Shannon
Publicado 2017

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B

por Sun, Haowei (Linda), Yang, Ming, Poon, Man‐Chiu, Lee, Adrienne, Robinson, K. Sue, Sholzberg, Michelle, Wu, John, Iorio, Alfonso, Blanchette, Victor, Carcao, Manuel, Klaassen, Robert J., Jackson, Shannon
Publicado 2021

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study

por Matino, Davide, Iorio, Alfonso, Keepanasseril, Arun, Germini, Federico, Caillaud, Alexandre, Carcao, Manuel, Hews‐Girard, Julia, Iserman, Emma, James, Paula, Lee, Adrienne, Phua, Chai W., Sun, Haowei (Linda), Teitel, Jerome, Poon, Man‐Chiu
Publicado 2022

Real‐world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune toleranc...

por Carcao, Manuel, Shapiro, Amy, Hwang, Nina, Pipe, Steven, Ahuja, Sanjay, Lieuw, Ken, Staber, Janice M., Belletrutti, Mark, Sun, Haowei Linda, Ding, Hilda, Wang, Michael, Price, Victoria, Steele, MacGregor, Tsao, Elisa, Feng, Jing, Al‐Khateeb, Zahra, Dumont, Jennifer, Jain, Nisha
Publicado 2020